MovDisordV3, PascalFrancis, Corpus, bibRecord, 000E70

Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism

Identifieur interne : 000E70 ( PascalFrancis/Corpus ); précédent : 000E69; suivant : 000E71

Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism

Auteurs : Sebastian Paus ; Franziska Gadow ; Michael Knapp ; Christine Klein ; Thomas Klockgether ; Ullrich Wüllner

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0257349

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Dyskinésie, Pathologie du système nerveux, Complication, Homme, Allemand, Polymorphisme, Lévodopa.

English descriptors

KwdEn :
- Complication, Dyskinesia, German, Human, Levodopa, Nervous system diseases, Parkinson disease, Polymorphism.

Abstract

In addition to levodopa treatment and disease duration, genetic predisposition might contribute to the development of medication-related complications in Parkinson's disease (PD). As recent observations indicate the dopamine D₃ receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Stepwise regression analysis revealed no effect of DRD3 Ser9Gly on chorea, dystonia, or motor fluctuations in PD, despite incorporating established clinical risk factors to avoid overlooking an effect of genotype. Duration of PD was confirmed as the most important clinical risk factor, followed by age of disease onset and female sex. Additional studies incorporating grading of motor complications, and combinations of risk genotypes, are warranted.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism`
A11	`01`	`1`		`@1 PAUS (Sebastian)`
A11	`02`	`1`		`@1 GADOW (Franziska)`
A11	`03`	`1`		`@1 KNAPP (Michael)`
A11	`04`	`1`		`@1 KLEIN (Christine)`
A11	`05`	`1`		`@1 KLOCKGETHER (Thomas)`
A11	`06`	`1`		`@1 WÜLLNER (Ullrich)`
A14	`01`			`@1 Department of Neurology, University of Bonn @2 Bonn @3 DEU @Z 1 aut. @Z 2 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn @2 Bonn @3 DEU @Z 3 aut.`
A14	`03`			`@1 Clinical and Molecular Neurogenetics, Department of Neurology, University of Luheck @2 Lubeck @3 DEU @Z 4 aut.`
A20				`@1 1080-1084`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000188271060210`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 24 ref.`
A47	`01`	`1`		`@0 09-0257349`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In addition to levodopa treatment and disease duration, genetic predisposition might contribute to the development of medication-related complications in Parkinson's disease (PD). As recent observations indicate the dopamine D₃ receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Stepwise regression analysis revealed no effect of DRD3 Ser9Gly on chorea, dystonia, or motor fluctuations in PD, despite incorporating established clinical risk factors to avoid overlooking an effect of genotype. Duration of PD was confirmed as the most important clinical risk factor, followed by age of disease onset and female sex. Additional studies incorporating grading of motor complications, and combinations of risk genotypes, are warranted.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Complication @5 09`
C03	`04`	`X`	`ENG`	`@0 Complication @5 09`
C03	`04`	`X`	`SPA`	`@0 Complicación @5 09`
C03	`05`	`X`	`FRE`	`@0 Homme @5 10`
C03	`05`	`X`	`ENG`	`@0 Human @5 10`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 10`
C03	`06`	`X`	`FRE`	`@0 Allemand @5 11`
C03	`06`	`X`	`ENG`	`@0 German @5 11`
C03	`06`	`X`	`SPA`	`@0 Alemán @5 11`
C03	`07`	`X`	`FRE`	`@0 Polymorphisme @5 12`
C03	`07`	`X`	`ENG`	`@0 Polymorphism @5 12`
C03	`07`	`X`	`SPA`	`@0 Polimorfismo @5 12`
C03	`08`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 13`
C03	`08`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 13`
C03	`08`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 13`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Mouvement involontaire @5 42`
C07	`05`	`X`	`ENG`	`@0 Involuntary movement @5 42`
C07	`05`	`X`	`SPA`	`@0 Movimiento involuntario @5 42`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 43`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 43`
N21				`@1 187`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0257349 INIST
ET :	Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism
AU :	PAUS (Sebastian); GADOW (Franziska); KNAPP (Michael); KLEIN (Christine); KLOCKGETHER (Thomas); WÜLLNER (Ullrich)
AF :	Department of Neurology, University of Bonn/Bonn/Allemagne (1 aut., 2 aut., 5 aut., 6 aut.); Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn/Bonn/Allemagne (3 aut.); Clinical and Molecular Neurogenetics, Department of Neurology, University of Luheck/Lubeck/Allemagne (4 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 7; Pp. 1080-1084; Bibl. 24 ref.
LA :	Anglais
EA :	In addition to levodopa treatment and disease duration, genetic predisposition might contribute to the development of medication-related complications in Parkinson's disease (PD). As recent observations indicate the dopamine D₃ receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Stepwise regression analysis revealed no effect of DRD3 Ser9Gly on chorea, dystonia, or motor fluctuations in PD, despite incorporating established clinical risk factors to avoid overlooking an effect of genotype. Duration of PD was confirmed as the most important clinical risk factor, followed by age of disease onset and female sex. Additional studies incorporating grading of motor complications, and combinations of risk genotypes, are warranted.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Dyskinésie; Pathologie du système nerveux; Complication; Homme; Allemand; Polymorphisme; Lévodopa
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Mouvement involontaire; Trouble neurologique
ED :	Parkinson disease; Dyskinesia; Nervous system diseases; Complication; Human; German; Polymorphism; Levodopa
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder
SD :	Parkinson enfermedad; Disquinesia; Sistema nervioso patología; Complicación; Hombre; Alemán; Polimorfismo; Levodopa
LO :	INIST-20953.354000188271060210
ID :	09-0257349

Links to Exploration step

Pascal:09-0257349

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism</title>
<author><name sortKey="Paus, Sebastian" sort="Paus, Sebastian" uniqKey="Paus S" first="Sebastian" last="Paus">Sebastian Paus</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gadow, Franziska" sort="Gadow, Franziska" uniqKey="Gadow F" first="Franziska" last="Gadow">Franziska Gadow</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knapp, Michael" sort="Knapp, Michael" uniqKey="Knapp M" first="Michael" last="Knapp">Michael Knapp</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Klein, Christine" sort="Klein, Christine" uniqKey="Klein C" first="Christine" last="Klein">Christine Klein</name>
<affiliation><inist:fA14 i1="03"><s1>Clinical and Molecular Neurogenetics, Department of Neurology, University of Luheck</s1>
<s2>Lubeck</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wullner, Ullrich" sort="Wullner, Ullrich" uniqKey="Wullner U" first="Ullrich" last="Wüllner">Ullrich Wüllner</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0257349</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0257349 INIST</idno>
<idno type="RBID">Pascal:09-0257349</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E70</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism</title>
<author><name sortKey="Paus, Sebastian" sort="Paus, Sebastian" uniqKey="Paus S" first="Sebastian" last="Paus">Sebastian Paus</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gadow, Franziska" sort="Gadow, Franziska" uniqKey="Gadow F" first="Franziska" last="Gadow">Franziska Gadow</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knapp, Michael" sort="Knapp, Michael" uniqKey="Knapp M" first="Michael" last="Knapp">Michael Knapp</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Klein, Christine" sort="Klein, Christine" uniqKey="Klein C" first="Christine" last="Klein">Christine Klein</name>
<affiliation><inist:fA14 i1="03"><s1>Clinical and Molecular Neurogenetics, Department of Neurology, University of Luheck</s1>
<s2>Lubeck</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Klockgether, Thomas" sort="Klockgether, Thomas" uniqKey="Klockgether T" first="Thomas" last="Klockgether">Thomas Klockgether</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wullner, Ullrich" sort="Wullner, Ullrich" uniqKey="Wullner U" first="Ullrich" last="Wüllner">Ullrich Wüllner</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Complication</term>
<term>Dyskinesia</term>
<term>German</term>
<term>Human</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Polymorphism</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Pathologie du   système nerveux</term>
<term>Complication</term>
<term>Homme</term>
<term>Allemand</term>
<term>Polymorphisme</term>
<term>Lévodopa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In addition to levodopa treatment and disease duration, genetic predisposition might contribute to the development of medication-related complications in Parkinson's disease (PD). As recent observations indicate the dopamine D<sub>3</sub>
 receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Stepwise regression analysis revealed no effect of DRD3 Ser9Gly on chorea, dystonia, or motor fluctuations in PD, despite incorporating established clinical risk factors to avoid overlooking an effect of genotype. Duration of PD was confirmed as the most important clinical risk factor, followed by age of disease onset and female sex. Additional studies incorporating grading of motor complications, and combinations of risk genotypes, are warranted.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PAUS (Sebastian)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GADOW (Franziska)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KNAPP (Michael)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KLEIN (Christine)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KLOCKGETHER (Thomas)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WÜLLNER (Ullrich)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn</s1>
<s2>Bonn</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Clinical and Molecular Neurogenetics, Department of Neurology, University of Luheck</s1>
<s2>Lubeck</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1080-1084</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000188271060210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0257349</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In addition to levodopa treatment and disease duration, genetic predisposition might contribute to the development of medication-related complications in Parkinson's disease (PD). As recent observations indicate the dopamine D<sub>3</sub>
 receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Stepwise regression analysis revealed no effect of DRD3 Ser9Gly on chorea, dystonia, or motor fluctuations in PD, despite incorporating established clinical risk factors to avoid overlooking an effect of genotype. Duration of PD was confirmed as the most important clinical risk factor, followed by age of disease onset and female sex. Additional studies incorporating grading of motor complications, and combinations of risk genotypes, are warranted.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Complication</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Complication</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Complicación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Allemand</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>German</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Alemán</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Polymorphisme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Polymorphism</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Polimorfismo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>43</s5>
</fC07>
<fN21><s1>187</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0257349 INIST</NO>
<ET>Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism</ET>
<AU>PAUS (Sebastian); GADOW (Franziska); KNAPP (Michael); KLEIN (Christine); KLOCKGETHER (Thomas); WÜLLNER (Ullrich)</AU>
<AF>Department of Neurology, University of Bonn/Bonn/Allemagne (1 aut., 2 aut., 5 aut., 6 aut.); Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn/Bonn/Allemagne (3 aut.); Clinical and Molecular Neurogenetics, Department of Neurology, University of Luheck/Lubeck/Allemagne (4 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 7; Pp. 1080-1084; Bibl. 24 ref.</SO>
<LA>Anglais</LA>
<EA>In addition to levodopa treatment and disease duration, genetic predisposition might contribute to the development of medication-related complications in Parkinson's disease (PD). As recent observations indicate the dopamine D<sub>3</sub>
 receptor (DRD3) to modulate both therapeutic action of levodopa and dyskinesia, we reappraised the impact of the DRD3 Ser9Gly polymorphism on development of motor complications in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Stepwise regression analysis revealed no effect of DRD3 Ser9Gly on chorea, dystonia, or motor fluctuations in PD, despite incorporating established clinical risk factors to avoid overlooking an effect of genotype. Duration of PD was confirmed as the most important clinical risk factor, followed by age of disease onset and female sex. Additional studies incorporating grading of motor complications, and combinations of risk genotypes, are warranted.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Dyskinésie; Pathologie du   système nerveux; Complication; Homme; Allemand; Polymorphisme; Lévodopa</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Mouvement involontaire; Trouble neurologique</FG>
<ED>Parkinson disease; Dyskinesia; Nervous system diseases; Complication; Human; German; Polymorphism; Levodopa</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder</EG>
<SD>Parkinson enfermedad; Disquinesia; Sistema nervioso patología; Complicación; Hombre; Alemán; Polimorfismo; Levodopa</SD>
<LO>INIST-20953.354000188271060210</LO>
<ID>09-0257349</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E70 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E70 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0257349
   |texte=   Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism

Motor Complications in Patients Form the German Competence Network on Parkinson's Disease and the DRD3 Ser9Gly Polymorphism

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri